Tal vez has escuchado muchos medicamentos para el tratamiento de la enfermedad por Coronavirus, ¿ pero realmente sabes cómo funcionan? o ¿ realmente sabes si funcionan?. No te pierdas este vídeo donde veremos las más importantes hasta ahora y los avances en su investigación.
EDICIÓN Y GRABACIÓN POR
– JC Brothers Inc.
.
SUSCRÍBETE: www.youtube.com/c/JuanCanoMD.
.
REFERENCIAS.
– Cloroquina e Hidroxicloroquina.
1. Wang M, Cao R, Zhang L et al. Remdesivir and chloroquine efficiently hinder the just recently emerged novel coronavirus (2019- nCoV) in vitro. Cell Res. 2020; 30: 269-271
Keyaerts E, Vijgen L, Maes P et al. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine.
Cortegiani A, Ingoglia G, Ippolito M et al. A methodical evaluation on the effectiveness and safety of chloroquine for the treatment of COVID-19
Gautret P, Lagier JC, Parola P et al. Hydroxychloroquine and azithromycin as a treatment of COVID -19: outcomes of an open-label non-randomized scientific trial. Coronavirus Illness 2019( COVID-19): Information for Clinicians on Therapeutic Choices for COVID-19 Patients.
CDC. Interim standards for collecting, managing, and testing medical specimens from persons for coronavirus disease 2019 (COVID-19). From CDC website ( https://www.cdc.gov/coronavirus/2019- nCoV/lab/guidelines-clinical-specimens. html)
– Remdesivir.
Agostini ML, Andres EL, Sims Air Conditioner et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease.
2. Brown AJ, Won JJ, Graham RL et al. Broad spectrum antiviral remdesivir prevents human endemic and zoonotic deltacoronaviruses with a highly divergent RNA reliant RNA polymerase. Antiviral Res. 2019; 169:104541
Compounds with therapeutic potential against novel respiratory 2019 coronavirus.2020
ESTUDIOS CLÍNICOS FASE III.
NCT04292899 – Study to evaluate the safety and antiviral activity of remdesivir (GS-5734) in participants with serious coronavirus illness (COVID-19). NCT04292899
NCT04292899).
2. NCT04292730 – Research study to examine the security and antiviral activity of remdesivir (GS-5734) in individuals with moderate coronavirus illness (COVID-19) compared to standard of care treatment. NCT04292730 ( https://www.clinicaltrials.gov/ct2/show/NCT04292730)
– Lopinavir/Ritonavir.
1. Chu CM, Cheng VC, Hung IF et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax.2004
Cao B, Wang Y, Wen D et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Serious Covid-19
Yao TT, Qian JD, Zhu WY et al. A methodical review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus illness-19 treatment alternative.
– Oseltamivir.
Chen N, Zhou M, Dong X et al. Epidemiological and scientific qualities of 99 cases of 2019 unique coronavirus pneumonia in Wuhan, China: a detailed study.
2. Tan EL, Ooi EE, Lin CY et al. Inhibition of SARS coronavirus infection in vitro with scientifically approved antiviral drugs. Emerg Infect Dis.2004
– Tocilizumab.
1. Xu X, Han M, Li T et al. Efficient treatment of extreme COVID-19 clients with Tocilizumab. Readily available on chinaXiv site. Accessed online 2020 Mar19
2. Mehta P, McAuley DF, Brown M et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 16: pii: S0140- 6736(20)30628 -0[Epub ahead of print]
ESTUDIOS CLÍNICOS FASE III.
NCT04317092 – U.S. National Library of Medicine. Accessed 2020 Apr 1. NLM identifier: NCT04317092
2. NCT04320615 – U.S. National Library of Medication. ClinicalTrials.gov. Accessed 2020 Apr 2. Readily available from https://clinicaltrials.gov/ct2/show/study/NCT04320615 NLM identifier: NCT04320615
– Azitromicina.
1. Molina JM, Delaugerre C, Goff JL, et al. No evidence of rapid antiviral clearance or medical advantage with the combination of hydroxychloroquine and azithromycin in patients with serious COVID19 infection. Médecine et Maladies Infectieuses.2020 Preprint. https://doi.org/doi: 101016/ j.medmal.202003006
2. Giudicessi JR, Noseworthy PA, Friedman PA et al. Immediate assistance for navigating and preventing the QTc prolonging and torsadogenic potential of possible pharmacotherapies for COVID19 Mayo Clin Proc. Preprint. DOI: 10.1016/ j.mayocp.202003024
Comments
Post a Comment